What is PHAT's current stock price?

PHAT (Phathom Pharmaceuticals, Inc.) is currently trading at $11.13 with a market cap of $887.5M.

What sector is Phathom Pharmaceuticals, Inc. in?

Phathom Pharmaceuticals, Inc. (PHAT) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is PHAT a good stock to buy?

Analysts have a Buy consensus on PHAT with a price target of $24.67. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

PHAT Phathom Pharmaceuticals, Inc.

Healthcare

$11.13+0.00%OpenMarket Cap: $887.5M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

-2.76

P/S

4.41

EV/EBITDA

-7.55

DCF Value

$-6.79

FCF Yield

-10.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

84.9%

Operating Margin

-47.1%

Net Margin

-76.8%

ROE

39.2%

ROA

-51.6%

ROIC

-53.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$58.3M	$-30.4M	$—
Q4 null	$57.6M	$-21.1M	$—
FY null	$175.1M	$-221.2M	$—
Q3 null	$49.5M	$-30.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$24.67

Target (Median)

$28.00

Target Range

$18.00 - $28.00

2 Strong Buy7 Buy1 Hold0 Sell0 Strong Sell

BarclaysOverweight

2026-03-27

GuggenheimBuy

2026-02-27

HC Wainwright & Co.Buy

2025-10-31

Craig-HallumBuy

2025-06-09

HC Wainwright & Co.Buy

2025-06-09

Trading Activity

Insider Trades

View All

Topper James Ndirector, 10 percent owner:

SellThu May 21

Stenhouse Markdirector

SellThu May 21

Schroeder Theodore Rdirector

SellThu May 21

Parikh Asitdirector

SellThu May 21

Parikh Asitdirector

SellThu May 21

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.57

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Peers

KOD

OCS